Journal profile · Toxicology
Immunopharmacology and Immunotoxicology
ISSN 0892-3973 · eISSN 1532-2513 · Informa Healthcare · UNITED STATES · Quarterly
Immunopharmacology and Immunotoxicology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.52; JCR Q2 (journal website); subscription journal; APC charged, amount not published; median 227 days to acceptance (96 articles, last 24 months); community-reported acceptance: easy; 83 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Immunopharmacology and Immunotoxicology is published by Informa Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immune Response and Inflammation, Immune Cell Function and Interaction and Immunotherapy and Immune Responses, together about 25.9% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
The journal Immunopharmacology and Immunotoxicology is devoted to the publication of manuscripts related to drug discovery, pre-clinical and clinical drug development of agents targeting the immune system, as well as immunotoxicology observations of defined drug compounds in general. In immunopharmacology science, the journal is particularly interested in areas such as anti-inflammatory treatments, cancer-immunotherapy and vaccines. Within immunotoxicology the journal will consider any pharmacological compound that affects the immune system. The journal will consider research related to the immunoregulatory effects of defined pharmacological agents independent of the entity, also including small-molecules, vaccines, biologics and cell-based therapies. The journal will focus on disease areas such as immune-mediated diseases and cancer immunology but will also cover other disease areas with an immunological component, e.g. immunopathology as part of infections, transplantations, allergy, chronic kidney disease, neuro-degenerative disorders, immunodeficiencies, neurology, inflammatory atherosclerosis and more. Manuscripts including the following content will be considered: Mechanism of action studies, including gene-activation studies In-vitro studies and pre-clinical animal studies Non-interventional and interventional clinical studies. Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).
From the journal's Aims & Scope
Research area (LetPub): Toxicology
Editor-in-chief Anders Elm PedersenPublisher website
Editorial board by country: none in mainland China; most named Italy 4, Denmark 4, Taiwan, China 1, Macau, China 1, United States 1 (15 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immune Response and InflammationImmunology and Microbiology10.5%
- Immune Cell Function and InteractionImmunology and Microbiology10%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.4%
- T-cell and B-cell ImmunologyImmunology and Microbiology5.4%
- Asthma and respiratory diseasesMedicine4.8%
- Toxin Mechanisms and ImmunotoxinsImmunology and Microbiology4.4%
- Pharmacological Effects of Natural CompoundsPharmacology, Toxicology and Pharmaceutics4.4%
- Mast cells and histamineImmunology and Microbiology4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Toxicology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Toxicology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Toxicology | Zone 3 |
| Minor | Immunology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
Other: Academic Search Complete, BIOBASE, Biological Abstracts, Biomedical Reference Collection: Comprehensive, BIOSIS Full Coverage Shared, BIOSIS Previews, Derwent Chimera, Derwent Drug File, ETOH, Journal Citation Reports/Science Edition, SciSearch, EMBIOLOGY, CABI, PopLine, SIIC CABI Global Health, Agricultural Economics Database, Animal Science Database, Environmental Science Database, Index Veterinarius, Leisure Tourism Database, Leisure; Recreation and Tourism Abstracts, Rural Development Abstracts, Soil Science Database, Soils and Fertilizers
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.52LetPub ·
- Impact factor (publisher) 2025
- 3.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.3Publisher website ·
- CiteScore 2026-06
- 5.3LetPub ·
- CiteScore (publisher) 2025
- 5.3Publisher website ·
- SJR 2026-06
- 0.72LetPub ·
- SJR (publisher) 2025
- 0.72Publisher website ·
- SNIP 2026-06
- 0.58LetPub ·
- SNIP (publisher) 2025
- 0.58Publisher website ·
- h-index
- 42LetPub ·
- h-index
- 74OpenAlex ·
- i10-index
- 1,387OpenAlex ·
- 2-year mean citedness
- 2.6OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 1.83%LetPub ·
Volume
- Articles per year
- 77LetPub ·
- Downloads per year (publisher)
- 76,000Publisher website ·
Articles by year OpenAlex count · 2,663 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 81 | 9 | 26 |
| 2025 | 83 | 11 | 209 |
| 2024 | 78 | 9 | 393 |
| 2023 | 64 | 17 | 542 |
| 2022 | 140 | 31 | 1,588 |
| 2021 | 94 | 20 | 1,839 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
227 daysMedian, submission to acceptance · P25–P75 141 days – 300 days
- Acceptance to online
- median 18 days (96 articles)
- Submission to online
- median 251 days
- Sample
- 96 articles with submission and acceptance dates (191 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher)
- 10%Publisher website ·
- Submission to first decision
- 16 daysPublisher website ·
- First decision after review
- 120 daysPublisher website ·
- Acceptance to publication
- 26 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted7
- brief communicationsImmunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinica…Length not stated
- clinical casesImmunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinica…Length not stated
- clinical trialsImmunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinica…Length not stated
- commentariesImmunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinica…Length not stated
- mini-reviewsImmunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinica…Length not stated
- original manuscriptsImmunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinica…Length not stated
- reviewsImmunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinica…Length not stated
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Hybrid open access journal, part of the Taylor & Francis Open Select publishing program. Model summary
Immunopharmacology and Immunotoxicology is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the dis…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- ISSN
- 0892-3973
- Electronic ISSN
- 1532-2513
- Latest issue on the website
- Volume 48, Issue 5 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Immunopharmacology and Immunotoxicology
What CAS zone is Immunopharmacology and Immunotoxicology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Immunopharmacology and Immunotoxicology is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology / Pharmacology & Pharmacy / Toxicology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Immunopharmacology and Immunotoxicology?
The latest impact factor listed by LetPub is 3.52; CiteScore 5.3, h-index 74.
How long does peer review take at Immunopharmacology and Immunotoxicology?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 227 days (interquartile range 141–300 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 10%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Immunopharmacology and Immunotoxicology in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Where are the editorial board members of Immunopharmacology and Immunotoxicology based?
Of the 15 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (4), Denmark (4) and Taiwan, China (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Immunopharmacology and Immunotoxicology?
According to LetPub and DOAJ records, Immunopharmacology and Immunotoxicology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Immunopharmacology and Immunotoxicology open access, and what is the APC?
Immunopharmacology and Immunotoxicology is a subscription journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .